ABC/3TC

DRUG6 trials

Sponsors

ViiV Healthcare, Gilead Sciences

Conditions

HIV InfectionsHIV-1 InfectionInfection, Human Immunodeficiency Virus I

Phase 2

A Dose-Range Finding Clinical Trial Study in Human Immunodeficiency Virus (HIV-1) Infected Treatment-Naive Adults

TerminatedNCT04493216

ViiV HealthcareHIV Infections

Start: 2020-11-18End: 2023-05-29Updated: 2024-06-26

Phase 3

A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily

CompletedNCT01227824

ViiV HealthcareInfection, Human Immunodeficiency Virus I

Start: 2010-10-19End: 2016-12-27Updated: 2018-10-09

Switch Study to Evaluate F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed on Regimens Containing ABC/3TC

CompletedNCT02469246

Gilead SciencesHIV-1 Infection

Start: 2015-06-29End: 2019-03-13Updated: 2019-10-25

Study to Evaluate the Safety and Efficacy of Switching From Regimens Consisting of Boosted Atazanavir or Darunavir Plus Either Emtricitabine/Tenofovir or Abacavir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV-1 Infected Adults

CompletedNCT02603107

Gilead SciencesHIV-1 Infection

Start: 2015-11-20End: 2019-12-23Updated: 2020-12-29

Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adults

CompletedNCT02605954

Gilead SciencesHIV-1 Infection

Start: 2015-11-18End: 2018-01-24Updated: 2018-11-14

Phase 4

Renal Effect of Stribild or Other Tenofovir DF-containing Regimens Compared to Ritonavir-boosted Atazanavir Plus Abacavir/Lamivudine in Antiretroviral Treatment-naive HIV-1 Infected Adults

CompletedNCT02246998

Gilead SciencesHIV-1 Infection

Start: 2014-12-15End: 2016-02-17Updated: 2018-01-03

Related Papers

Efficacy and safety of the HIV-1 maturation inhibitor GSK3640254 plus two NRTIs in adults naive to antiretroviral therapy (DOMINO): 24-week results from a randomised phase 2b study.

2025-10-17

Efficacy and safety of switching to bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed Asian adults living with HIV: A pooled analysis from three international phase III randomized trials

HIV Medicine2022-08-178 citations

Relative Bioavailability and Food Effect of GSK3640254 Tablet and Capsule Formulations in Healthy Participants

Clinical Pharmacology in Drug Development2022-01-075 citations

Phase IIa Proof-of-Concept Evaluation of the Antiviral Efficacy, Safety, Tolerability, and Pharmacokinetics of the Next-Generation Maturation Inhibitor GSK3640254

Clinical Infectious Diseases2022-01-0520 citations

A Phase I Evaluation of the Pharmacokinetics and Tolerability of the HIV-1 Maturation Inhibitor GSK3640254 and Tenofovir Alafenamide/Emtricitabine in Healthy Participants.

2021-05-1812 citations

Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, phase 3, non-inferiority trial.

2018-06-18125 citations

Tenofovir alafenamide plus emtricitabine versus abacavir plus lamivudine for treatment of virologically suppressed HIV-1-infected adults: a randomised, double-blind, active-controlled, non-inferiority phase 3 trial.

2018-02-2016 citations

Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study.

2013-01-08418 citations